An FDA Nominee, Biologics Reviews Move to CDER

The FDA's recent announcement that the responsibility for reviewing biologics would be transferred from the Center for Biological Research (CBER) to the Center for Drug Evaluation and Research came amidst growing industry and congressional criticism about CBER's handling of Biologics Licensing Applications (BLAs). But the FDA's failure to spell out the details of the reorganization leaves many questions unanswered, among them: what will be the implications for biogenerics; how will CBER's funding be affected; and what will be the impact on pending BLAs?

Biotech companies have been fuming for some time about the handling of Biologics Licensing Applications (BLAs) by the FDA's Center for Biologics Research and Evaluation (CBER). The complaints include prolonged approval times (an average 19.6 months last year for BLAs versus 16.4 months for New Drug Applications reviewed by the Center for Drug Evaluation and Research (CDER)), as well as inconsistencies between the handling of approval applications by CBER and by CDER. A particular sore point concerns CBER's failure to employ Special Protocol Assessments (SPAs)—written contracts between sponsors and the FDA that, by including specifications regarding the design of pivotal studies, make it more difficult for the agency to change the rules midstream. In the five years since Congress authorized the use of SPAs, CDER has entered into more than 120 such agreements to CBER's one.

Indeed, Congress—probably the single most effective motivator for FDA change, good or bad—has made clear its dissatisfaction with the way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.